Recently, immune checkpoint inhibitors, particularly those targeting CTLA-4 and PD-1/PD-L1 pathways, have shown remarkable anti-tumor effects across various cancer types, marking a transformative era in cancer treatment. Here, CTLA4 is linked to neoplasm.